Working… Menu

Advanced Glycation Endproducts and Bone Material Strength in T2D Treated With Pyridoxamine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03778580
Recruitment Status : Active, not recruiting
First Posted : December 19, 2018
Last Update Posted : July 28, 2021
Information provided by (Responsible Party):
Mishaela Rubin, Columbia University

Brief Summary:
The purpose of this study is to determine if a specific form of Vitamin B known as Pyridoxamine helps improve bone strength over one year in women (>65 yrs old) with Type 2 Diabetes. The investigators know that people with type 2 diabetes have the lower bone material strength and the investigators suspect this is due to high levels of circulating sugars that build up over time (known as Advanced Glycation Endproducts). The investigators will study whether using a specific form of vitamin B, known as pyridoxamine helps improve bone strength and reduce levels of circulating sugars over a one year time period.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Dietary Supplement: Pyridoxamine Dihydrochloride Drug: placebo Not Applicable

Detailed Description:
Type 2 Diabetes Mellitus (T2DM) has become one of the most important diseases of our time. Recent research shows that diabetes has negative effects on bones and that people with diabetes might more likely to break a bone. The investigators don't know the reasons for this, but the investigators suspect that normal bone replacement is slowed down in diabetes and this could slow down the growth of new bone. It is possible that the normal material becomes weaker because sugar-related components ("Advanced Glycation Endproducts") are making the bone more brittle. The investigators have shown in past research that people who have type 2 diabetes are more likely to have both weaker bone with lower "bone material strength" and also higher level of sugar-related components("Advanced Glycation Endproducts"). This study will focus on attempting to lower the sugar-related components("Advanced Glycation Endproducts") by treating a group of patients with type 2 diabetes with an over- the- counter B vitamin, known as vitamin B6 or pyridoxamine for one year. The investigators will compare post-menopausal women both before and after pyridoxamine use and study them in terms of different bone features based on blood tests, bone imaging, a bone indentation test and a measurement of sugar-related components in the skin. This study will help to clarify if using pyridoxamine helps improve bone strength in women with diabetes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes Treated With Pyridoxamine
Actual Study Start Date : March 1, 2018
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : February 28, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: pyridoxamine
pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid for one year
Dietary Supplement: Pyridoxamine Dihydrochloride
pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid

Placebo Comparator: identical placebo
identical placebo po bid for one year
Drug: placebo

Primary Outcome Measures :
  1. Bone formation in serum by P1NP [ Time Frame: 12 months ]
    change in serum biochemical marker of bone formation, P1NP

Secondary Outcome Measures :
  1. Advanced glycation endproducts [ Time Frame: 12 months ]
    Skin assessment of advanced glycation endproducts

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal women ≥65 years
  • Diagnosis of T2D for ≥ 5 years, with all HbA1c levels.

Exclusion Criteria:

  • Hormone replacement treatment (HTR) use (to avoid the influence of estrogen).
  • Fractures (excluding skull, facial bones, metacarpals, fingers, toes, and fractures associated with severe trauma) within 12 months.
  • A history of pathological fractures (eg, due to Paget's disease, myeloma, metastatic malignancy).
  • Type 1 diabetes
  • Disorders associated with altered skeletal structure or function (chronic liver disease' chronic renal disease stage 4 [eGFR < 30 mL/mim/1.73 m2] or worse, malignancy, hypoparathyroidism or hyperparathyroidism,acromegaly, Cushing's syndrome, hypopituitarism, alcohol intake > 3U/day).
  • Treatment with any of the following drugs in part year:current corticosteroid, anticonvulsant therapy(phenytoin, phenobarbital, primidone, carbamazepine), SGLT2 inhibitor if on it for < 1 year), pharmacological doses of thyroid hormone (TSH<normal), adrenal or anabolic steroids, Aromatase inhibitors, calcitonin, bisphosphonates, denosumab, estrogen, or selective estrogen receptor modulator, sodium fluoride, teriparatide, thiazolidinediones(TZDs).
  • Serum 25(OH)D levels < 20 ng/ml. If 25(OH)D levels are < 20 ng/ml, rescreening will be allowed following a vitamin D loading regimen of 50,000 IU/week for 4 weeks. If serum 25(OH) D levels are ≥ 20 ng/ml after supplementation, the subject will be allowed to enroll.
  • Current use of pyridoxamine (although not multivitamin or vitamin B6 users because pyridoxamine is not at pharmacologic levels in these supplements).
  • Allergy to pyridoxamine and vitamin B6.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03778580

Layout table for location information
United States, New York
Columbia University Medical Center - Harkness Pavillion
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Layout table for investigator information
Principal Investigator: Mishaela Rubin,, M.D Columbia University
  Study Documents (Full-Text)

Documents provided by Mishaela Rubin, Columbia University:
Study Protocol  [PDF] October 10, 2018

Layout table for additonal information
Responsible Party: Mishaela Rubin, Associate Professor of Medicine, Columbia University Identifier: NCT03778580    
Other Study ID Numbers: AAAR5451
First Posted: December 19, 2018    Key Record Dates
Last Update Posted: July 28, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mishaela Rubin, Columbia University:
Vitamin B6
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs